Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Drops By 53.9%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 6,135 shares, a drop of 53.9% from the April 30th total of 13,319 shares. Based on an average trading volume of 56,976 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Genenta Science Stock Performance

Shares of GNTA traded up $0.14 during trading hours on Friday, reaching $1.03. The company had a trading volume of 819,079 shares, compared to its average volume of 507,535. The firm has a 50 day simple moving average of $0.69 and a 200-day simple moving average of $1.12. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16. Genenta Science has a 12-month low of $0.55 and a 12-month high of $10.00.

Genenta Science (NASDAQ:GNTA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.28.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

A number of large investors have recently made changes to their positions in GNTA. Citadel Advisors LLC purchased a new position in shares of Genenta Science in the 3rd quarter valued at about $41,000. Eurizon Capital SGR S.p.A. purchased a new position in Genenta Science during the 4th quarter valued at about $536,000. Norges Bank purchased a new position in Genenta Science during the 4th quarter valued at about $337,000. SmartHarvest Portfolios LLC purchased a new position in Genenta Science during the 4th quarter valued at about $26,000. Finally, Alyeska Investment Group L.P. purchased a new position in Genenta Science during the 4th quarter valued at about $328,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.